EBV-Positive Diffuse Large B-Cell Lymphoma EBV+ DLBCL

EBV-Positive DLBCL is a distinct subtype of aggressive B-cell lymphoma in which Epstein-Barr virus (EBV) actively drives lymphoma cell growth and survival. It is diagnosed by detecting EBV RNA (EBER) within the tumour cells using a special staining technique called EBER ISH. It most commonly affects older adults due to age-related immune decline but also occurs in immunocompromised individuals (HIV, transplant recipients). It is generally more difficult to treat than EBV-negative DLBCL and may benefit from EBV-specific therapeutic approaches.

While sharing the same large B-cell morphology, EBV+ DLBCL has distinct molecular biology driven by viral oncoproteins (LMP1, EBNA2) that activate cancer-promoting signalling pathways and cause high PD-L1 expression for immune evasion. It tends to have a worse prognosis with standard R-CHOP chemotherapy and creates unique therapeutic opportunities targeting EBV-specific antigens — such as EBV-specific T-cell therapy — not applicable in EBV-negative disease.

EBER ISH (EBV-Encoded RNA in Situ Hybridisation) performed on the tumour biopsy tissue is the definitive test. It detects viral RNA within individual tumour cells. Blood EBV antibody tests or EBV viral load testing alone cannot establish the diagnosis. If your biopsy was not tested with EBER ISH, a specialist centre can perform this test on archival tissue.

HIV infection, particularly at low CD4 counts, impairs the immune system's ability to control EBV-infected B-cells, significantly increasing the risk of EBV-driven lymphomas including EBV+ DLBCL. Treatment requires both antiretroviral therapy (ART) to restore immune function and lymphoma-directed chemotherapy. Effective ART optimisation before and during treatment is an important component of management.

Some patients — particularly those with limited-stage disease, good performance status, and effective immune reconstitution — can achieve durable remission with R-CHOP-based therapy. However, outcomes are generally less favourable than EBV-negative DLBCL. Novel approaches including EBV-specific T-cell therapies, checkpoint inhibitors exploiting high PD-L1, bispecific antibodies, and CAR-T cell therapy for relapsed disease are improving the therapeutic landscape.

EBV-specific cytotoxic T-lymphocyte (EBV-CTL) therapy involves expanding T-cells that specifically recognise and kill EBV-infected tumour cells. This approach has established efficacy in EBV-associated post-transplant lymphoproliferative disorder (PTLD) and is being investigated in EBV+ DLBCL. It is available at specialist centres through clinical trials or compassionate access programmes — CancerFax can help coordinate access.

EBV-driven lymphoma cells express viral proteins that activate anti-apoptotic pathways (NF-κB, PI3K, JAK-STAT), making them more resistant to chemotherapy-induced cell death. EBV also induces high PD-L1 expression, enabling the lymphoma to evade host immune responses that would otherwise augment chemotherapy effectiveness. These mechanisms explain the inferior R-CHOP outcomes and justify EBV-directed novel approaches.

Yes. CancerFax assists patients with EBV+ DLBCL through biopsy and EBER ISH report review, coordination of specialist second opinions with lymphoma haematologists experienced in EBV-driven diseases, and access to EBV-specific T-cell therapy programmes, checkpoint immunotherapy trials, CAR-T cell therapy, and bispecific antibody access — including options through centres in China and internationally. Whether you are newly diagnosed, have relapsed after R-CHOP, or are exploring novel approaches, our team can help identify the most appropriate pathway for your specific situation.